Potential Drug Targets for Alzheimer's and Other Neurological Disorders

Target Name: PTPN22

NCBI ID: G26191

PTPN22

Potential Drug Targets for Alzheimer's and Other Neurological Disorders

PTPN22 (lyp1) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the neurotransmitter transporter family 2 (NMT), which is responsible for transporting neurotransmitters across the brain-cell membrane.

In recent years, researchers have been interested in studying the potential drug targets of PTPN22 because of its involvement in the development of neurological disorders. Studies have shown that PTPN22 is expressed in the brains of individuals with Alzheimer's disease and that its levels are decreased in the brains of individuals with the disease. This suggests that PTPN22 may be a potential drug target for Alzheimer's disease.

In addition to its involvement in Alzheimer's disease, PTPN22 has also been shown to be involved in the development of other neurological disorders, including Parkinson's disease and multiple sclerosis. Studies have shown that individuals with these disorders have lower levels of PTPN22 in their brains compared to healthy individuals.

The exact mechanism by which PTPN22 contributes to the development and progression of these disorders is not yet fully understood. However, research has shown that PTPN22 plays a role in the regulation of the neurotransmitterter neurotrophic factor (NTF), which is a protein that promotes the survival and proliferation of brain cells.

Research has also shown that PTPN22 is involved in the regulation of the protein brain-derived neurotrophic factor (BDNF), which is a protein that promotes the growth and survival of brain cells. This suggests that PTPN22 may be involved in the development and progression of neurological disorders by regulating the activity of these two proteins.

In conclusion, PTPN22 is a protein that is expressed in the brain and is involved in the development and progression of various neurological disorders, including Alzheimer's disease. Its involvement in the regulation of neurotransmitter transport and the regulation of brain-derived neurotrophic factor suggests that it may be a potential drug target for these disorders. Further research is needed to fully understand the role of PTPN22 in the development and progression of neurological disorders.

Protein Name: Protein Tyrosine Phosphatase Non-receptor Type 22

Functions: Acts as negative regulator of T-cell receptor (TCR) signaling by direct dephosphorylation of the Src family kinases LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and other key signaling molecules (PubMed:16461343, PubMed:18056643). Associates with and probably dephosphorylates CBL. Dephosphorylates LCK at its activating 'Tyr-394' residue (PubMed:21719704). Dephosphorylates ZAP70 at its activating 'Tyr-493' residue (PubMed:16461343). Dephosphorylates the immune system activator SKAP2 (PubMed:21719704). Positively regulates toll-like receptor (TLR)-induced type 1 interferon production (PubMed:23871208). Promotes host antiviral responses mediated by type 1 interferon (By similarity). Regulates NOD2-induced pro-inflammatory cytokine secretion and autophagy (PubMed:23991106). Acts as an activator of NLRP3 inflammasome assembly by mediating dephosphorylation of 'Tyr-861' of NLRP3 (PubMed:27043286). Dephosphorylates phospho-anandamide (p-AEA), an endocannabinoid to anandamide (also called N-arachidonoylethanolamide) (By similarity)

The "PTPN22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTPN22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets